Transcatheter Bicaval Valve Implantation For Treatment Of Severe Tricuspid Regurgitation: A Single Centre Registry
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Heterotopic caval valve implantation using the TricValve ® (OrbusNeich P&F) is a unique interventional approach for treatment of severe Tricuspid Regurgitation in patients who are deemed ineligible for surgery. Given the complexity and novelty of TricValve ® implantation, there is a pressing need for robust clinical data to evaluate its safety, efficacy, and long-term outcomes. Our study assesses the clinical results of patients followed up for 1 year from our centre.
Methods
Retrospective, single centre registry involving patients who have undergone TricValve ® Transcatheter Bicaval Valves System (OrbusNeich P&F) implantation for the treatment of severe tricuspid regurgitation.
Results
Fourteen patients were included. The mean age was 67.5 ± 8.7 years, with high surgical risk (mean EuroSCORE II 6.1 ± 3.7). Procedural success was achieved in thirteen patients, with no reported in-hospital mortality or stroke among all fourteen patients. At 1-year, significant improvements were observed in New York Heart Association (NYHA) functional class (86% Class III at baseline to 0% Class III at 1 year, P=0.002) and Kansas City Cardiomyopathy Questionnaire (KCCQ-12) scores (mean 32.0 ± 7.4 to 42.4 ± 12.0, P=0.015). TR Regurgitant Volume significantly decreased (65.5 ± 16.9 ml to 38.2 ± 13.6 ml, P=0.005). No deaths or strokes occurred during follow-up. Rehospitalization due to heart failure occurred in 14% (2 out of 14) of patients.
Conclusion
In this single-centre registry of high-risk patients, TricValve ® implantation was associated with a favorable safety profile, significant reduction in tricuspid regurgitant volume, and meaningful improvements in functional status and quality of life at 1 year.
Clinical Perspective
What is New?
-
This registry provides the first single-centre experience from a national heart centre in Asia evaluating the feasibility and safety of the TricValve transcatheter system.
-
The study offers unique real-world data on procedural outcomes and patient selection specifically within an underrepresented Asia-Pacific population.
-
Our findings demonstrate that caval valve implantation is a technically viable therapeutic option for Asian patients with severe tricuspid regurgitation and prohibitive surgical risk.
What are the Clinical Implications?
-
These results support the broader adoption of transcatheter caval therapies as a safe alternative for managing refractory right heart failure in the region.
-
The observed short-term clinical improvements suggest that this intervention can effectively reduce the burden of recurrent hospitalizations in high-risk patients.
-
This evidence contributes to the development of standardized procedural protocols for emerging right-sided structural heart programs in Asian medical centres.
